Stock Events

Marinus Pharmaceuticals 

$1.44
31
+$0+0% Today

Statistics

Day High
1.44
Day Low
1.44
52W High
11.24
52W Low
1.5
Volume
100
Avg. Volume
499
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

8MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.76
0.12
1.01
1.89
Expected EPS
-0.66
Actual EPS
-0.68

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0JYL.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sage Therapeutics
SAGE
Mkt Cap739.64M
Sage Therapeutics competes directly with Marinus in developing treatments for central nervous system disorders, including postpartum depression and major depressive disorder, areas Marinus is also targeting.
Jazz Pharmaceuticals
JAZZ
Mkt Cap6.87B
Jazz Pharmaceuticals, after acquiring GW Pharmaceuticals, continues to compete in the epilepsy market, particularly with treatments like Epidiolex, which competes with Marinus's seizure disorder treatments.
Supernus Pharmaceuticals
SUPN
Mkt Cap1.66B
Supernus Pharmaceuticals has a focus on central nervous system diseases, including epilepsy, where it has several marketed products that compete with Marinus's developmental epilepsy treatments.
LAVA Therapeutics NV
LVTX
Mkt Cap54.16M
Lava Therapeutics is engaged in developing bispecific antibodies aimed at treating cancer, which could compete with Marinus's efforts in developing treatments for rare seizure disorders, as both target niche, high-need patient populations.
Palatin Technologies
PTN
Mkt Cap27.92M
Palatin Technologies works on developing therapeutics for diseases with a focus on central nervous system disorders, which could place it in competition with Marinus for similar target markets.
Biogen
BIIB
Mkt Cap32.96B
Biogen focuses on neurology, including multiple sclerosis and spinal muscular atrophy, and its broad focus on the central nervous system could see it competing with Marinus in neurological treatment areas.
Pfizer
PFE
Mkt Cap169.83B
Pfizer, with its vast portfolio including treatments for central nervous system disorders, represents a broader competitor to Marinus, especially as it continues to expand its neurological disease treatment offerings.

About

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Show more...
CEO
Dr. Scott N. Braunstein M.D.
Employees
113
Country
United States
ISIN
US56854Q2003
WKN
000A2QEUC

Listings